JO
OKUR

John Overdeck’s OnKure Therapeutics OKUR Stock Holding History

John Overdeck’s Portfolio OKUR Stock Details OKUR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$496K Buy
108,870
+84,608
+349% +$363K ﹤0.01% 4166
2026
Q1 		$100K Buy
24,262
+12,942
+114% +$40K ﹤0.01% 4386
2025
Q4 		$32.8K Sell
11,320
-14,115
-55% -$42.3K ﹤0.01% 3969
2025
Q3 		$69.9K Sell
25,435
-427
-2% -$1.06K ﹤0.01% 3510
2025
Q2 		$61.8K Sell
25,862
-1,286
-5% -$3.37K ﹤0.01% 3051
2025
Q1 		$117K Buy
+27,148
New +$153K ﹤0.01% 2947
2024
Q4 		– Sell
-13,533
Closed -$230K – 3552
2024
Q3 		$230K Buy
13,533
+2,347
+21% +$34.7K ﹤0.01% 2766
2024
Q2 		$169K Sell
11,186
-1,873
-14% -$31.8K ﹤0.01% 2762
2024
Q1 		$217K Sell
13,059
-5,188
-28% -$85.6K ﹤0.01% 2685
2023
Q4 		$292K Buy
+18,247
New +$1.14M ﹤0.01% 2708

Other funds holding OKUR

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return
SG
StepStone Group La Jolla, California $2.16B AUM 20.11% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $630M AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

John Overdeck's OKUR Position: Q2 2026 in Review

John Overdeck increased its OnKure Therapeutics (OKUR) stake by 349% in Q2 2026, buying an estimated $363K and bringing the position to 108,870 shares worth $496K. The position accounts for ﹤0.01% of the portfolio, ranked #4166.

John Overdeck first reported a position in OKUR in Q4 2023 and has held it in 10 quarters since. 75 funds tracked by Wall St. Rank hold OKUR as of Q2 2026.

  • John Overdeck held 108,870 shares of OnKure Therapeutics worth $496K as of Q2 2026.
  • John Overdeck bought 84,608 OnKure Therapeutics shares in Q2 2026, an estimated $363K.
  • OnKure Therapeutics made up ﹤0.01% of John Overdeck's portfolio in Q2 2026, its #4166 holding.
  • John Overdeck first reported a position in OnKure Therapeutics in Q4 2023 and has held it in 10 quarters since.
  • 75 funds tracked by Wall St. Rank held OnKure Therapeutics as of Q2 2026.

Based on Two Sigma Investments's 13F filing for Q2 2026, filed 14 Aug 2026.